Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

11.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies02:49

Cancer Therapies

10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Cancer Survival Analysis01:21

Cancer Survival Analysis

808
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
808

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of ion acceleration and diffusion in a laser-driven magnetized plasma.

Nature communications·2026
Same author

Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results.

Cancer medicine·2025
Same author

Dysbiotic Microbiome-Metabolome Axis in Childhood Obesity and Metabolic Syndrome.

Journal of dental research·2025
Same author

Prospective Multicenter Observational Study of Patients in Shock Treated with Vasopressin: VASOPRES Registry Study Protocol.

Revista espanola de anestesiologia y reanimacion·2025
Same author

Cohort study to evaluate the pattern of analgesic prescription in adult patients undergoing ambulatory surgery.

Revista espanola de anestesiologia y reanimacion..·2025
Same author

Shock wave formation in radiative plasmas.

Physical review. E·2024

Related Experiment Video

Updated: Mar 12, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Accrual to Cancer Clinical Trial.

C Kelly1, M Smith1, S Flynn1

  • 1Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7.

Irish Medical Journal
|November 12, 2016
PubMed
Summary

Only 5% of eligible cancer patients enrolled in clinical trials, with most trials lacking options for specific cancer types, stages, or treatment lines. Increased support is needed to double enrollment rates and expand patient options.

More Related Videos

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.3K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.7K

Related Experiment Videos

Last Updated: Mar 12, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.3K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.7K

Area of Science:

  • Oncology
  • Clinical Research

Background:

  • Accrual to cancer clinical trials (CCT) is crucial for advancing cancer treatment and improving patient outcomes.
  • International accrual rates to CCTs remain low, highlighting a gap in patient access to novel therapies.

Purpose of the Study:

  • To evaluate the accrual rate of patients starting a new anti-cancer agent to CCTs.
  • To identify barriers to CCT enrollment in a north Dublin cancer center.

Main Methods:

  • Retrospective chart review of 140 patients starting a new anti-cancer agent between November 2015 and February 2016.
  • Analysis of patient data to determine CCT eligibility, availability, and reasons for non-accrual.

Main Results:

  • Only 29% of patients had a CCT option available.
  • The overall accrual rate to CCT was 5% (7 out of 140 patients).
  • Key barriers included lack of CCT options for specific cancer types (23%), stages (19%), and treatment lines (17%).

Conclusions:

  • Accrual to CCTs in this center is comparable to international figures, but remains suboptimal.
  • Significant barriers exist, necessitating targeted interventions to increase patient access.
  • Continued governmental and philanthropic support is vital to expand CCT options and achieve a 10% accrual target.